Identification of immune cell infiltration pattern and related critical genes in metastatic castration-resistant prostate cancer by bioinformatics analysis

被引:7
|
作者
Fan, Caibin [1 ]
Lu, Wei [2 ]
Li, Kai [1 ]
Zhao, Chunchun [1 ]
Wang, Fei [1 ]
Ding, Guanxiong [3 ]
Wang, Jianqing [1 ]
机构
[1] Nanjing Med Univ, Affiliated Suzhou Hosp, Suzhou Municipal Hosp, Gusu Sch,Dept Urol, 26 Daoqian Rd, Suzhou 215000, Jiangsu, Peoples R China
[2] Suzhou Vocat Hlth Coll, Sch Nursing, Suzhou, Jiangsu, Peoples R China
[3] Fudan Univ, Huashan Hosp, Dept Urol, Shanghai, Peoples R China
基金
中国国家自然科学基金;
关键词
Immune infiltration; metastatic castration resistant prostate cancer (mCRPC); RNA sequencing; bioinformatics analysis; immunotherapy; DIFFERENTIAL EXPRESSION ANALYSIS; BREAST-CANCER; IMMUNOTHERAPY; SURVIVAL; INTERLEUKIN-2; PROLIFERATION; ENZALUTAMIDE; ANTAGONISTS; INHIBITION; DIAGNOSIS;
D O I
10.3233/CBM-203222
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: Metastatic castration-resistant prostate cancer (mCRPC) is the lethal stage of prostate cancer and the main cause of morbidity and mortality, which is also a potential target for immunotherapy. METHOD: In this study, using the Approximate Relative Subset of RNA Transcripts (CIBERSORT) online method, we analysed the immune cell abundance ratio of each sample in the mCRPC dataset. The EdgeR (an R package) was used to classify differentially expressed genes (DEGs). Using the Database for annotation, visualisation and interactive exploration (DAVID) online method, we performed functional enrichment analyses. STRING online database and Cytoscape tools have been used to analyse protein-protein interaction (PPI) and classify hub genes. RESULTS: The profiles of immune infiltration in mCRPC showed that Macrophages M2, Macrophages M0, T cells CD4 memory resting, T cells CD8 and Plasma cells were the main infiltration cell types in mCRPC samples. Macrophage M0 and T cell CD4 memory resting abundance ratios were correlated with clinical outcomes. We identified 1102 differentially expressed genes (DEGs) associated with the above two immune cells to further explore the underlying mechanisms. Enrichment analysis found that DEGs were substantially enriched in immune response, cell metastasis, and metabolism related categories. We identified 20 hub genes by the protein-protein interaction network analysis. Further analysis showed that three critical hub genes, CCR5, COL1A1 and CXCR3, were significantly associated with prostate cancer prognosis. CONCLUSION: Our findings revealed the pattern of immune cell infiltration in mCRPC, and identified the types and genes of immune cells correlated with clinical outcomes. A new theoretical basis for immunotherapy may be given by our results.
引用
收藏
页码:363 / 377
页数:15
相关论文
共 50 条
  • [21] Cabazitaxel in metastatic castration-resistant prostate cancer
    Yap, Timothy A.
    Pezaro, Carmel J.
    de Bono, Johann S.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (09) : 1129 - 1136
  • [22] A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates
    Jochems, Caroline
    Tucker, Jo A.
    Tsang, Kwong-Yok
    Madan, Ravi A.
    Dahut, William L.
    Liewehr, David J.
    Steinberg, Seth M.
    Gulley, James L.
    Schlom, Jeffrey
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2014, 63 (04) : 407 - 418
  • [23] Identification of DNA damage response-related genes as biomarkers for castration-resistant prostate cancer
    Oshima, Masashi
    Takayama, Ken-ichi
    Yamada, Yuta
    Kimura, Naoki
    Kume, Haruki
    Fujimura, Tetsuya
    Inoue, Satoshi
    SCIENTIFIC REPORTS, 2023, 13 (01):
  • [24] Optimal Therapy Sequencing in Metastatic Castration-Resistant Prostate Cancer
    Abouharb, Sausan
    Corn, Paul G.
    CURRENT ONCOLOGY REPORTS, 2013, 15 (03) : 217 - 223
  • [25] Sipuleucel-T In Metastatic Castration-Resistant Prostate Cancer
    Plosker, Greg L.
    DRUGS, 2011, 71 (01) : 101 - 108
  • [26] Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer
    Bansal, Dhruv
    Reimers, Melissa A.
    Knoche, Eric M.
    Pachynski, Russell K.
    CANCERS, 2021, 13 (02) : 1 - 22
  • [27] Sequencing Systemic Therapies in Metastatic Castration-Resistant Prostate Cancer
    Liu, Jane Jijun
    Zhang, Jingsong
    CANCER CONTROL, 2013, 20 (03) : 181 - 187
  • [28] Identification of key enzalutamide-resistance-related genes in castration-resistant prostate cancer and verification of RAD51 functions
    Xu, Wen
    Liu, Li
    Cui, Zhongqi
    Li, Mingyang
    Ni, Jinliang
    Huang, Nan
    Zhang, Yue
    Luo, Jie
    Sun, Limei
    Sun, Fenyong
    OPEN MEDICINE, 2023, 18 (01):
  • [29] Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer
    MacVicar, Gary R.
    Hussain, Maha H.
    CURRENT OPINION IN ONCOLOGY, 2013, 25 (03) : 252 - 260
  • [30] Prevalence of mutations in DNA repair genes in Russian patients with metastatic castration-resistant prostate cancer
    Mailyan, O. A.
    Kalpinskiy, A. S.
    Reshetov, I., V
    Anzhiganova, Yu, V
    Nyushko, K. M.
    Golovashchenko, M. P.
    Kokin, S. P.
    Stakanov, V. A.
    Alekseev, B. Ya
    ONKOUROLOGIYA, 2022, 18 (03): : 60 - 66